Management of androgenetic alopecia

Journal of the European Academy of Dermatology and Venereology

Volumn 12, Issue 3, 1999, Pages 205-214

  Tosti, A ^a   Camacho Martinez, F ^b   Dawber, R ^c  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF SEVILLE   (Spain)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

5 reductase; Alopecia; Androgens; Finasteride; Minoxidil

Indexed keywords

ANTIANDROGEN; MINOXIDIL;

ALOPECIA; FEMALE; HUMAN; MALE; REVIEW;

ALOPECIA; ANDROGEN ANTAGONISTS; FEMALE; HUMANS; MALE; MINOXIDIL;

EID: 0033127976     PISSN: 09269959     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-3083.1999.tb01030.x     Document Type: Article

References (46)

1. Drake LA, Dinehart SM, Farmer ER, et al.'Guidelines of care for androgenetic alopecia. J Am Acad Dermatol 1996;35:465-469.
2. Hamilton JB. Patterned hair loss in man: types and incidence. Ann NY Acad Sei 1951;53:708-728.
3. Ludwig E. Classification of the types of androgenetic alopecia (common baldness) arising in the female sex. Br J Dermatol 1977;97:249-256.
4. Rushton DH, et al. Natural progression of male pattern baldness in young men. Clin Exp Dermatol 1991;16:188-192.
5. Yenning VA, Dawber RPR. Patterned androgenetic alopecia in women. J Am Acad Dermatol 1988;18:1073-1077.
6. Kuster W, Happle R. The inheritance of common baldness: two B or not two B? J Am Acad Dermatol 1984;11:921-926.
7. Chen W. Zouboulis. Ch.C., Orfanos, C.E. The 5a-reductase system and its inhibitors. Dermatology 1996;193:177-184.
8. Whiting DA. Male pattern hair loss: current understanding. Int J Dermatol 1998;37:561-566.
9. Sawaya ME, Price VH. Different levels of 5a-reductase type I and II, aromatase, and androgen receptor in hair follicles of women and men with androgenetic alopecia. J Invest Dermatol 1997;109:296-300.
10. Eicheler W, Happle R, Hoffmann R. 5a-reductase activity in the human hair follicle concentrates in the dermal papilla. Arch Dermatol Res 1998;290:126-132.
11. Chen W, Zouboulis ChC, Fritsch M, et al. Evidence of heterogeneity and quantitative differences of the type 1 5a-reductase expression in cultured human skin cells. First evidence of its presence in melanocytes. J Invest Dermatol 1998;! 10:84-89.
12. Bayne EB, Flanagan J, Einstein M, et al. Immunohistochemical localization of types I and II 5a-reductase in human scalp. J Invest Dermatol, submitted.
13. Imperato-McGinley J, Guerrero L, Gautier T, et al. Steroid 5ot-reductase deficiency in man: an inherited form of male pseudohermaphroditism. Science 1974;186:1213-1215.
14. Bingham KD, Shaw DA. The metabolism of testosterone by human male scalp skin. J Endocrinol 1973;57:111-121.
15. Courtois M, Loussauam G, Hourseau C, et al. Ageing and hair cycles. Br J Dermatol 1995;132:86-93.
16. Guarrera M, Rebora A. Anagen hairs may fail to replace telogen hairs in early androgenetic female alopecia. Dermatology 1996; 192:28-31.
17. Parakkal PF. Catagen and telogen phases of the growth cycle. In: Orfanos CE, Happle R, editors. Hair and Hair Diseases. Berlin: Springer, 1990.
18. Kozlowoska U, Blume-Peytavi U, Kodelja V, et al. Expression of vascular endothelial growth factor (VEGF) in various compartments of the human hair follicle. Arch Dermatol Res 1988:290:661-668.
19. Whiting DA. Diagnostic and predictive value of horizontal sections of scalp biopsy specimens in male pattern androgenetic alopecia. J Am Acad Dermatol 1993;28:754-763.
20. Sudduth St, Koronkowski MJ. Finasteride:the first 5a-reductase inhibitor. Pharmacotherapy 1993:13:309-325.
21. Gorinley GJ. Finasteride:a clinical review. Biomed Pharmacother 1995;49:319-324.
22. Dallob AL, Sadick NS, Unger W, et al. The effect of finasteride, a 5a-reductase inhibitor, on scalp skin testosterone and dihydrotestosterone concentrations in patients with male pattern baldness. J Clin Endocrinol Metab 1994;79:703-706.
23. Rhodes L, Harper J, Uno H, et al. The effects of finasteride (Proscar) on hair growth, hair cycle stage, and serum testosterone and dihydrotestosterone in adult male and female stumptail macaque monkeys (Macaca arctiodes). J Clin Endrocrinol Metab 1994;79:991-996.
24. Kaufman KD, Olsen EA, Whiting D, et al. Finasteride in the treatment of men with androgenetica alopecia. J Am Acad Dermatol 1998:39:578-589.
25. Leyden J, Dunlap F, Miller B, et al. Finasteride in the treatment of men with frontal male pattern hair loss. J Am Acad Dermatol 1999;40:930-937.
26. Buhl A. Minoxidil's action in hair follicles. J Invest Dermatol 1991:96:735-748.
27. Ohtsuyama M, Morhashi M. Minoxidil sulphate effect on internal calcium of cell in the epidermis and epidermal appendages. In: Van Neste DJJ, Randall VA, editors. Hair Research for the Next Millennium. Amsterdam: Eisevier Science, 1996.
28. Lachgar S, Charveron M, Gall Y, et al. Minoxidil upregulates thé expression of vascular endothelial growth factor in human hair dermal papilla cells. Br J Dermatol 1998;138:407-411.
29. De Villez R, Jacobs J, Szpunar C, et al. Androgenetic alopecia in the female. Treatment with 2% minoxidil solution. Arch Dermatol 1994;130:303-307.
30. Olsen E. Treatment of androgenetic alopecia with topical minoxidil. Res Staff Phys 1989;35:53.
31. Price VH, Menefee E. Quantitative estimation of hair growth: comparative changes in weight and hair count with 5% and 2% minoxidil, placebo and no treatment. In: Van Neste DJJ, Randall VA, editors. Hair Research for the Next Millennium. Amsterdam: Elsevier Science, 1996. pp. 67-71.
32. Trancik R. 5% topical minoxidil in the treatment of male androgenetic alopecia. Poster presented at the 2nd Intercontinental Meeting of Hair Research Societies. Washington DC 1998;5-7:41.
33. Tosti A, Guerra L, Bardazzi F. Contact dermatitis caused by topical minoxidil: case reports and review of the literature. Am J Contact Dermal 1991;2:56-59.
34. Peluso AM, Misciali C, Vincenzi C, et al. Diffuse hypertrichosis during treatment with 5% topical minoxidil. Br J Dermatol 1997;136:118.
35. Elias P. Epidermal effects of retinoids: supramolecular observations and clinical implications. J Am Acad Dermatol 1986; 15:797.
36. Bazzano G, Terezakis N, Galen W. Topical tretinoin for hair growth promotion. J Am Acad Dermatol 1986;15:880.
37. Unger WP. Surgical approach to hair loss. In: Olsen E, editor. Disorders of hair growth. Diagnosis and treatment. New York: McGraw-Hill, 1994.
38. Olimori K. Microsurgical free temporoparietal flaps in surgery for male pattern baldness. Clin Plastic Surg 1991;18:791-796.
39. Lucas MW. Recent advances in hair transplantation. Skin Pharmacol 1994;7:105-108.
40. Roberts J, Hordinsky M, Olsen E. The Effects of Finasteride on Post-Menopausal Women with Androgenetic Alopecia. Bruxelles: Hair Workshop, 1998.
41. Dawber RPR, Sonnex T, Ralfs I. Oral antiandrogen treatment of common baldness in women. Br J Dermatol 1982; 107(Suppl):22:20.
42. Ekoe J, Burckhardt P, Ruedr B. Treatment of hirsutism, acne and alopecia with cyproterone acetate. Dermatologica 1980; 160:398.
43. Rushton DH, Rammsay ID. The importance of adequate serum ferritin levels during oral cyproterone acetate and ethinyl oestradiol treatment of diffuse androgen-dependent alopecia in women. Clin Endocrinol 1992;36:421-427.
44. Menard G, Guenther T, Kon H, et al. Studies on the destruction of adrenal and testicular cytochrome P450 by spironolac-tone. J Biol Chem 1979;254:1726.
45. Burke B, Cunliffe W. Oral spironolactone therapy for female patients with acne, hirsutism and androgenetic alopecia. Br J Dermatol 1985;! 12:124-125.
46. Rushton HD, et al. Quantitative assessment of spironolactone treatment in women with diffuse androgenetic alopecia. J Soc Cosmet Chem 1991;42:317.